Literature DB >> 30849393

ADAR1: A New Target for Immuno-oncology Therapy.

Amruta Bhate1, Tao Sun1, Jin Billy Li2.   

Abstract

Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30849393     DOI： 10.1016/j.molcel.2019.02.021

Source DB:  PubMed          Journal:  Mol Cell        ISSN： 1097-2765            Impact factor:   17.970


  18 in total

Review 1.  Cellular RNA surveillance in health and disease.

Authors:  Sandra L Wolin; Lynne E Maquat
Journal:  Science       Date:  2019-11-14       Impact factor: 47.728

2.  Unbiased Identification of trans Regulators of ADAR and A-to-I RNA Editing.

Authors:  Emily C Freund; Anne L Sapiro; Qin Li; Sandra Linder; James J Moresco; John R Yates; Jin Billy Li
Journal:  Cell Rep       Date:  2020-05-19       Impact factor: 9.423

Review 3.  How RNA modifications regulate the antiviral response.

Authors:  Matthew G Thompson; Matthew T Sacco; Stacy M Horner
Journal:  Immunol Rev       Date:  2021-08-17       Impact factor: 12.988

Review 4.  A Dual Role of DDX3X in dsRNA-Derived Innate Immune Signaling.

Authors:  Juntae Kwon; Hyeongjwa Choi; Cecil Han
Journal:  Front Mol Biosci       Date:  2022-07-06

5.  Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response.

Authors:  Hyeongjwa Choi; Juntae Kwon; Min Soon Cho; Yifan Sun; Xiaofeng Zheng; Jing Wang; Kerrie B Bouker; John L Casey; Michael B Atkins; Jeffrey Toretsky; Cecil Han
Journal:  Cancer Res       Date:  2021-05-03       Impact factor: 12.701

Review 6.  ADAR1: "Editor-in-Chief" of Cytoplasmic Innate Immunity.

Authors:  Mart M Lamers; Bernadette G van den Hoogen; Bart L Haagmans
Journal:  Front Immunol       Date:  2019-07-25       Impact factor: 7.561

7.  ADAR1 Alleviates Inflammation in a Murine Sepsis Model via the ADAR1-miR-30a-SOCS3 Axis.

Authors:  Zhou Shangxun; Li Junjie; Zhao Wei; Wang Yutong; Jia Wenyuan; Liu Shanshou; Wang Yanjun; Wang Qianmei; Feng Zhusheng; Yu Chaoping; Zhuang Ran; Yin Wen; Huang Yang
Journal:  Mediators Inflamm       Date:  2020-03-24       Impact factor: 4.711

Review 8.  A-to-I RNA Editing in Cancer: From Evaluating the Editing Level to Exploring the Editing Effects.

Authors:  Heming Wang; Sinuo Chen; Jiayi Wei; Guangqi Song; Yicheng Zhao
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

Review 9.  The role of RNA editing enzyme ADAR1 in human disease.

Authors:  Brian Song; Yusuke Shiromoto; Moeko Minakuchi; Kazuko Nishikura
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-06-08       Impact factor: 9.957

10.  High-throughput mutagenesis reveals unique structural features of human ADAR1.

Authors:  SeHee Park; Erin E Doherty; Yixuan Xie; Anil K Padyana; Fang Fang; Yue Zhang; Agya Karki; Carlito B Lebrilla; Justin B Siegel; Peter A Beal
Journal:  Nat Commun       Date:  2020-10-12       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.